Literature DB >> 30224247

Colorectal peritoneal carcinomatosis: What is the future of HIPEC?

François Quénet1.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 30224247     DOI： 10.1016/j.ejso.2018.08.009

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN： 0748-7983            Impact factor:   4.424


× No keyword cloud information.
  2 in total

1.  GECOP-MMC: phase IV randomized clinical trial to evaluate the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) with mytomicin-C after complete surgical cytoreduction in patients with colon cancer peritoneal metastases.

Authors:  Fernando Pereira; Angel Serrano; Israel Manzanedo; Estibalitz Pérez-Viejo; Santiago González-Moreno; Luis González-Bayón; Alvaro Arjona-Sánchez; Juan Torres; Isabel Ramos; Maria E Barrios; Pedro Cascales; Rafael Morales; Enrique Boldó; Alfonso García-Fadrique; Xabier Arteaga; Alberto Gutierrez-Calvo; Susana Sánchez-García; Enrique Asensio; Cesar P Ramírez; Manuel Artiles; Javier Vaqué; Pedro A Parra; Pedro Villarejo; Cristóbal Muñoz-Casares; Estrella Turienzo; Alicia Calero; Isabel Jaén Torrejimeno; Isabel Prieto; Julio Galindo; Vicente Borrego; Manuel E Marcello; Cristina Rihuete; Joaquin Carrasco; Luis Gomez-Quiles
Journal:  BMC Cancer       Date:  2022-05-12       Impact factor: 4.638

2.  Study of oxaliplatin penetration into ovaries of patients treated with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal metastases of colorectal and appendiceal origin using mass spectrometry imaging.

Authors:  Marion Larroque; Sandra Mounicou; Olivia Sgarbura; Carine Arnaudguilhem; Lucie Rebel; Cristina Leaha; Pierre-Arnaud Faye; Christine Enjalbal; François Quénet; Brice Bouyssiere; Sébastien Carrere
Journal:  Pleura Peritoneum       Date:  2021-03-24
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.